Myriad Genetics Inc (NASDAQ:MYGN)

26.68
Delayed Data
As of Jan 22
 -0.02 / -0.07%
Today’s Change
9.24
Today|||52-Week Range
30.13
+34.92%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.0B

Company Description

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Contact Information

Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City Utah 84108
P:(801) 584-3600
Investor Relations:
(801) 584-1143

Employees

Shareholders

Individual stakeholders6.29%
Other institutional53.95%
Mutual fund holders46.36%

Top Executives

Paul J. DiazPresident, Chief Executive Officer & Director
R. Bryan RiggsbeeChief Financial Officer, Treasurer & Executive VP
Robert Gardner HarrisonChief Information Officer
Jerry S. LanchburyChief Scientific Officer
Clivetty MartinezChief Compliance Officer